High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: An important role of bone marrow as a secondary lymphoid organ

Cancer Science

Volumn 101, Issue 4, 2010, Pages 848-854

  Murao, Ayako ^a   Oka, Yoshihiro ^a   Tsuboi, Akihiro ^b   Elisseeva, Olga A ^b   Tanaka Harada, Yukie ^a   Fujiki, Fumihiro ^b   Nakajima, Hiroko ^b   Nishida, Sumiyuki ^b   Hosen, Naoki ^c   Shirakata, Toshiaki ^d   Hashimoto, Nobuyuki ^e   Myoui, Akira ^f   Ueda, Takafumi ^g   Takeda, Yoshito ^a   Osaki, Tadashi ^h   Enomoto, Takayuki ^e   Yoshikawa, Hideki ^e   Kimura, Tadashi ^e   Oji, Yusuke ^d   Kawase, Ichiro ^a   Sugiyama, Haruo ^b   more..

^a Allergy and Rheumatic Diseases   (Japan)

^b Cancer Immunotherapy ^*  (Japan)

^c Cancer Stem Cell Biology   (Japan)

^d Biomedical Informatics   (Japan)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f OSAKA UNIVERSITY HOSPITAL   (Japan)

^g OSAKA NATIONAL HOSPITAL   (Japan)

^h Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD45RA ANTIGEN; CD57 ANTIGEN; CHEMOKINE RECEPTOR CCR7; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; TUMOR PROTEIN; UNCLASSIFIED DRUG; WILM TUMOR PROTEIN 1; CD45 ANTIGEN; WT1 PROTEIN;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD; BONE MARROW; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MALE; MEMORY T LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; SOLID TUMOR; T LYMPHOCYTE SUBPOPULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMISTRY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ADOLESCENT; AGED; ANTIGENS, CD45; BONE MARROW; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NEOPLASMS; WT1 PROTEINS;

EID: 77957266756     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01468.x     Document Type: Article

References (56)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8.
2. Malmberg KJ, Ljunggren HG. Escape from immune- and nonimmune-mediated tumor surveillance. Semin Cancer Biol 2006; 16: 16-31.
3. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006; 211: 214-24.
4. Ibegbu CC, Xu YX, Harris W, Maggio D, Miller JD, Kourtis AP. Expression of killer cell lectin-like receptor G1 on antigen-specific human CD8+ T lymphocytes during active, latent, and resolved infection and its relation with CD57. J Immunol 2005; 174: 6088-94.
5. Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004; 101: 13885-90.
6. Pittet MJ, Speiser DE, Lienard D et al. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res 2001; 7: 796s-803s.
7. Walker EB, Haley D, Miller W et al. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin Cancer Res 2004; 10: 668-80.
8. Romero P, Valmori D, Pittet MJ et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev 2002; 188: 81-96.
9. Letsch A, Knoedler M, Na IK et al. CMV-specific central memory T cells reside in bone marrow. Eur J Immunol 2007; 37: 3063-8.
10. Cavanagh LL, Bonasio R, Mazo IB et al. Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells. Nat Immunol 2005; 6: 1029-37.
11. Feuerer M, Beckhove P, Garbi N et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med 2003; 9: 1151-7.
12. Di Rosa F, Pabst R. The bone marrow: a nest for migratory memory T cells. Trends Immunol 2005; 26: 360-6.
13. Bonasio R, von Andrian UH. Generation, migration and function of circulating dendritic cells. Curr Opin Immunol 2006; 18: 503-11.
14. Becker TC, Coley SM, Wherry EJ, Ahmed R. Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J Immunol 2005; 174: 1269-73.
15. Di Rosa F, Santoni A. Bone marrow CD8 T cells are in a different activation state than those in lymphoid periphery. Eur J Immunol 2002; 32: 1873-80.
16. Parretta E, Cassese G, Barba P, Santoni A, Guardiola J, Di Rosa F. CD8 cell division maintaining cytotoxic memory occurs predominantly in the bone marrow. J Immunol 2005; 174: 7654-64.
17. Cassese G, Parretta E, Pisapia L, Santoni A, Guardiola J, Di Rosa F. Bone marrow CD8 cells down-modulate membrane IL-7Ralpha expression and exhibit increased STAT-5 and p38 MAPK phosphorylation in the organ environment. Blood 2007; 110: 1960-9.
18. Mazo IB, Honczarenko M, Leung H et al. Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. Immunity 2005; 22: 259-70.
19. Oji Y, Miyoshi S, Maeda H et al. Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 2002; 100: 297-303.
20. Oji Y, Ogawa H, Tamaki H et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999; 90: 194-204.
21. Oji Y, Suzuki T, Nakano Y et al. Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumors. Cancer Sci 2004; 95: 822-7.
22. Oka Y, Tsuboi A, Kawakami M et al. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr Med Chem 2006; 13: 2345-52.
23. Sugiyama H. Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 2001; 73: 177-87.
24. Oka Y, Udaka K, Tsuboi A et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 2000; 164: 1873-80.
25. Oka Y, Elisseeva OA, Tsuboi A et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000; 51: 99-107.
26. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000; 95: 286-93.
27. *2402-binding residues. Cancer Immunol Immunother 2002; 51: 614-20.
28. Elisseeva OA, Oka Y, Tsuboi A et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002; 99: 3272-9.
29. Tsuboi A, Oka Y, Osaki T et al. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases. Microbiol Immunol 2004; 48: 175-84.
30. Oka Y, Tsuboi A, Murakami M et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 2003; 78: 56-61.
31. Oka Y, Tsuboi A, Elisseeva OA et al. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers. ScientificWorldJournal 2007; 7: 649-65.
32. Izumoto S, Tsuboi A, Oka Y et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 2008; 108: 963-71.
33. Iiyama T, Udaka K, Takeda S et al. WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 2007; 51: 519-30.
34. Rezvani K, Yong AS, Mielke S et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236-42.
35. Bozzacco L, Trumpfheller C, Siegal FP et al. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A 2007; 104: 1289-94.
36. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-12.
37. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000; 18: 593-620.
38. Monteiro J, Batliwalla F, Ostrer H, Gregersen PK. Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J Immunol 1996; 156: 3587-90.
39. Weng NP, Akbar AN, Goronzy J. CD28(-) T cells: their role in the age-associated decline of immune function. Trends Immunol 2009; 30: 306-12.
40. Rubio V, Stuge TB, Singh N et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003; 9: 1377-82.
41. Di Rosa F. T-lymphocyte interaction with stromal, bone and hematopoietic cells in the bone marrow. Immunol Cell Biol 2009; 87: 20-9.
42. Feuerer M, Beckhove P, Bai L et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001; 7: 452-8.
43. Beckhove P, Feuerer M, Dolenc M et al. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest 2004; 114: 67-76.
44. Price PW, Cerny J. Characterization of CD4+ T cells in mouse bone marrow I. Increased activated/memory phenotype and altered TCR Vbeta repertoire. Eur J Immunol 1999; 29: 1051-6.
45. Slifka MK, Whitmire JK, Ahmed R. Bone marrow contains virus-specific cytotoxic T lymphocytes. Blood 1997; 90: 2103-8.
46. Zhang X, Dong H, Lin W et al. Human bone marrow: a reservoir for "enhanced effector memory" CD8+ T cells with potent recall function. J Immunol 2006; 177: 6730-7.
47. Tokoyoda K, Zehentmeier S, Hegazy AN et al. Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow. Immunity 2009; 30: 721-30.
48. Racanelli V, Frassanito MA, Leone P, Brunetti C, Ruggieri S, Dammacco F. Bone marrow of persistently hepatitis C virus-infected individuals accumulates memory CD8+ T cells specific for current and historical viral antigens: a study in patients with benign hematological disorders. J Immunol 2007; 179: 5387-98.
49. Palendira U, Chinn R, Raza W et al. Selective accumulation of virus-specific CD8+ T cells with unique homing phenotype within the human bone marrow. Blood 2008; 112: 3293-302.
50. Sze DM, Giesajtis G, Brown RD et al. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood 2001; 98: 2817-27.
51. Champagne P, Ogg GS, King AS et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001; 410: 106-11.
52. Bandres E, Merino J, Vazquez B et al. The increase of IFN-gamma production through aging correlates with the expanded CD8(+high)CD28(-)CD57(+) subpopulation. Clin Immunol 2000; 96: 230-5.
53. Brenchley JM, Karandikar NJ, Betts MR et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003; 101: 2711-20.
54. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996; 184: 1101-9.
55. Peled A, Grabovsky V, Habler L et al. The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. J Clin Invest 1999; 104: 1199-211.
56. Brouty-Boye D, Doucet C, Clay D, Le Bousse-Kerdiles MC, Lampidis TJ, Azzarone B. Phenotypic diversity in human fibroblasts from myelometaplasic and non-myelometaplasic hematopoietic tissues. Int J Cancer 1998; 76: 767-73.